Catalent re-ups manufacturing deal for Pfizer Liqui-Gels

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/daizuoxin)
(Image: iStock/daizuoxin)

Related tags Manufacturing

Catalent Pharma Solutions has signed an exclusive long-term supply agreement with Pfizer.

As part of the agreement, Catalent has formulated and is manufacturing Pfizer’s new Advil Liqui-Gels Minis using its softgel platform OptiGel™ Mini technology.

The technology helps improve absorption and enables higher API concentrations into smaller capsules.

The agreement follows a 20-year collaboration on the development and manufacture of Advil® Liqui-Gels® (ibuprofen).

Catalent is manufacturing the product at its St. Petersburg, Florida, facility.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Webinars

Headlines